Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today on 20 May 2020 held its Annual General Meeting (AGM). A summary of the resolutions follows.
NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed wi ...
NeuroVive completes recruitment in the second part of its ongoing KL1333 clinical Phase Ia/b study
Lund, Sweden, 20 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's on ...
NeuroVive announces settlement in dispute with CicloMulsion AG
Lund, Sweden, 16 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certa ...
NeuroVive’s NeuroSTAT project receives FDA Fast Track designation
Lund, Sweden, 27 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to s ...
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
Lund, Sweden, 4 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study wit ...
NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA
Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational ...
NeuroVive announces ruling from Supreme Court in case between the company and CicloMulsion AG
Lund, 30 April, 2019- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the Supreme Court had delivered its ruling concerning arbitration between NeuroVive and Cic ...
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 25 April 2019, NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today on 25 April 2019 held its Annual General Meeting (AGM). A summary of the resolutions follows.
NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study
Lund, Sweden, 19 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study has been screen ...
NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds
Lund, Sweden, 21 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of ...
NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue
In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.